Page 553«..1020..552553554555..560570..»

Ageless Regenerative Medical: Regenerative Medicine …

Posted: January 5, 2022 at 2:00 am

Ageless Regenerative Medical

The most profound influences on your health are the cumulative effects of the choices you make about your diet and lifestyle. Over 80% percent of the signs of aging and disease are caused by your lifestyle behaviors. At Ageless Regenerative Medical in Nashville, Tennessee, our team, led by Dr. Nicholas Sieveking andJan Stanley, RN, MS, focuses on a set of principles that empower you to make those critical lifestyle choices needed to not only look young but also feel young and live longer.

Our mission is to deliver quality care based on compassion and clinical excellence to patients who want to optimize their health and achieve an individualized age management solution. We take an integrative approach to functional and regenerative medicine. Treatments are individualized to meet patients needs and monitored closely to evaluate outcomes accurately and effectively.

Functional medicine evaluates the root causes of disease using a whole systems approach based on genetic, biochemical, and lifestyle factors. Most importantly, it is an individualized partnership that is developed between the patient and practitioner.

Regenerative medicine, an emerging branch of medical science, deals with the functional restoration of tissues or organs for the patient suffering from severe injuries, chronic disease, or for those wishing to improve their overall health. The progress in this field of research has laid the foundation for cell-based therapies of disease which cannot be cured by conventional medicine. The human body can heal itself and fight illnesses through its immune system. Regenerative therapies infuse cells to replace damaged ones as well as initiate growth factors to restore tissues and organ functions.

Learn More

See the original post:
Ageless Regenerative Medical: Regenerative Medicine ...

Posted in Regenerative Medicine | Comments Off on Ageless Regenerative Medical: Regenerative Medicine …

Placental Stem Cell Therapy Market to Surpass US$ 4.4 Bn by 2030, Underpinned by Enormous R&D in Cellular Therapies and Regenerative Medicine, Finds…

Posted: January 5, 2022 at 2:00 am

ALBANY, N.Y., Jan. 3, 2022 /PRNewswire/ -- Transparency Market Research: Companies in the placental stem cell therapy market have been recently exploring the therapeutic potential of mesenchymal stromal/stem cells (MSCs) for treating severe COVID-19. Particularly in acute respiratory distress syndrome (ARDS), MSCs have demonstrated high efficacy and safety, due to their immunomodulation and differentiation properties. The revenue in the global market is estimated to surpass US$ 4.4 Bn by 2030.H

A growing number of preclinical and clinical studies are exploring new therapeutic approaches utilizing placental MSCs for lung diseases, idiopathic pulmonary fibrosis (IPF), and cystic fibrosis (CF). This has extended the sales revenue potential, assert analysts in a TMR study on the placental stem cell therapy market.

Asia Pacific held a leading share of the global placental stem cell therapy market in 2019. Enormous R&D in regenerative therapies in the region has spurred lucrative opportunities for players in recent years.

Request Brochure of Placental Stem Cell Therapy MarketResearch Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=81612

Evaluation of safety and effectiveness of transplantation of human amniotic epithelial cells (hAECs) in various inflammatory and immune-based diseases. These have generated groundswell of attention, notably due to their ease of isolation, abundance, and non-immunogenic and non-tumorigenic properties. Moreover, ongoing clinical studies in hAECs are expected to pave way to innovative regenerative medicines for wound healing.

Key Findings of Placental Stem Cell Therapy Market Study

Request for Analysis of COVID-19 Impact on Placental Stem Cell Therapy Markethttps://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=81612

Such advances have supported substantial R&D funding on cell transplantation therapy in retinitis pigmentosa, thereby opening a new frontier, concurs the TMR study on the placental stem cell therapy market. In particular, transplantation of bone marrow-derived mesenchymal stem cells (BMSCs) is attracting special attention.

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough, Request for Custom Research- https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=81612

Placental Stem Cell Therapy Market: Key Drivers

Buy Placental Stem Cell Therapy MarketReport https://www.transparencymarketresearch.com/checkout.php?rep_id=81612&ltype=S

Placental Stem Cell Therapy Market: Key Players

Some of the key players in the placental stem cell therapy market are

Global Placental Stem Cell Therapy Market: Segmentation

Placental Stem Cell Therapy Market,by Application

Placental Stem Cell Therapy Market, by End User

Placental Stem Cell Therapy Market, by Region

Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Latest Healthcare Industry Research Reportsby Transparency Market Research:

Surgical Kits Market: The surgical kits market is projected to reach the valuation of US$ 40 Bn by 2031. Companies are unlocking growth opportunities in dentistry to introduce digital revolution. For instance, DIO Implant - an implant services provider is gaining recognition for its DIOnavi surgical kit, which supports the basics of digital implant dentistry.

Downstream Processing Market: The latest advancements in downstream processing include ligand technologies for purifying RNA and COVID-19 vaccines. Companies in the downstream processing market are in many talks such as Navigo Proteins and Repligan, who have developed an affinity ligand targeting the SARS-CoV-2 spike protein for the purification of COVID-19 vaccines.

Central Lab Market: The central lab market is estimated to surpass US$4.1Bn mark by2030. However, central lab stakeholders are posed with many challenges, such as time consuming processes, since several sites samples need to reach one lab and may take several days.

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update -https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street, Suite 700,Albany NY 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: [emailprotected]Follow Us: Twitter | LinkedInBlog: https://tmrblog.comBrowse PR - https://www.transparencymarketresearch.com/pressrelease/placental-stem-cell-therapy-market.htm

SOURCE Transparency Market Research

See more here:
Placental Stem Cell Therapy Market to Surpass US$ 4.4 Bn by 2030, Underpinned by Enormous R&D in Cellular Therapies and Regenerative Medicine, Finds...

Posted in Regenerative Medicine | Comments Off on Placental Stem Cell Therapy Market to Surpass US$ 4.4 Bn by 2030, Underpinned by Enormous R&D in Cellular Therapies and Regenerative Medicine, Finds…

Worldwide Regenerative Medicine Outlook to 2027: Therapeutics Segment Dominated the Market in 2020 Due to the High Usage of Primary Cell-Based…

Posted: January 5, 2022 at 2:00 am

DUBLIN, Dec. 29, 2021 /PRNewswire/ -- The "Global Regenerative Medicine Market Size, Share & Trends Analysis Report by Product (Cell-based Immunotherapies, Gene Therapies), by Therapeutic Category (Cardiovascular, Oncology), and Segment Forecasts, 2021-2027" report has been added to ResearchAndMarkets.com's offering.

Research and Markets

The global regenerative medicine market size is expected to reach USD 57.08 billion by 2027, growing at a CAGR of 11.27% over the forecast period.

Recent advancements in biological therapies have resulted in a gradual shift in preference toward personalized medicinal strategies over the conventional treatment approach. This has resulted in rising R&D activities in the regenerative medicine arena for the development of novel regenerative therapies.

Furthermore, advancements in cell biology, genomics research, and gene-editing technology are anticipated to fuel the growth of the industry. Stem cell-based regenerative therapies are in clinical trials, which may help restore damaged specialized cells in many serious and fatal diseases, such as cancer, Alzheimer's, neurodegenerative diseases, and spinal cord injuries.

For instance, various research institutes have adopted Human Embryonic Stem Cells (hESCs) to develop a treatment for Age-related Macular Degeneration (AMD).

Constant advancements in molecular medicines have led to the development of gene-based therapy, which utilizes targeted delivery of DNA as a medicine to fight against various disorders.

Gene therapy developments are high in oncology due to the rising prevalence and genetically driven pathophysiology of cancer. The steady commercial success of gene therapies is expected to accelerate the growth of the global market over the forecast period.

Regenerative Medicine Market Report Highlights

The number of companies engaged in the development of advanced therapies is continuously increasing over the past few years. This is anticipated to increase the competition among companies to create a specific and efficient pipeline

The therapeutics segment dominated the market in 2020 due to the high usage of primary cell-based therapies along with advances in stem cell and progenitor cell therapies. The implementation of these therapies in dermatological, musculoskeletal, and dental application results in the highest share of this segment

Stem cell and progenitor cell-based therapies are anticipated to witness rapid growth due to high investments in this research space and an increasing number of stem cell banks

With the rise in R&D and clinical trials of regenerative medicines, key players are offering several consulting services leading to lucrative growth of the services segment

The oncology segment is estimated to account for the largest revenue share by 2027 owing to the high prevalence of cancer indications, which drives the demand for better solutions. The presence of a strong pipeline of regenerative medicines for cancer treatment also supplements the segment growth

North America dominated the market in 2020 and is projected to continue its dominance over the forecast period. A significant number of universities and research organizations investigating various stem cell-based approaches for regenerative apposition in the U.S. propels the region's growth

Asia Pacific is projected to witness the fastest CAGR over the forecast period due to the emergence of key players and rapid adoption of cell-based approaches in the healthcare

Key Topics Covered:

Story continues

Market Variables, Trends, & Scope

Market Driver Analysis

Presence of a strong pipeline and a large number of clinical trials

High economic impact of regenerative medicine

Emerging applications of gene therapy in regenerative medicine

Increasing government & private funding to support the development of regenerative medicine

Technological advancements in regenerative medicine (stem cell, tissue engineering, and nanotechnology)

Increase in strategic partnerships to accelerate development & commercialization of regenerative medicines

Rising prevalence of chronic diseases & genetic disorders, degenerative diseases, and bone & joint diseases leading to rise in demand for regenerative treatments

Market Restraint Analysis

High cost of treatment

Regulatory issues pertaining to stem cells, tissues engineering, and regenerative medicines

Market Challenge Analysis

Current challenges of on-market gene therapies

Penetration & Growth Prospect Mapping for Therapeutic Category, 2020

Reimbursement Framework

Reimbursement Framework & Clinical Translation of RM

Reimbursement Framework for RM: Europe

Reimbursement Framework for RM: South Korea

Technology Overview

Autologous Cell Transplantation

Next-Generation Cell-Based Therapies

CAR-T Cell Technologies

Cost Structure Analysis

User Perspective Analysis

Market Influencer Analysis

Consumer Behavior Analysis

Regenerative Medicine Market - SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)

Industry Analysis - Porter's

Regenerative Medicine Market Analysis Tools

Major Deals & Strategic Alliances Analysis

Merger & Acquisition Deals

Collaboration & Partnerships

Business Expansion

Market Entry Strategies

Pharmaceutical and biotechnology companies

Raw material supplier

Contract Service Provider

Distributor

Companion Diagnostics companies:

Case Studies

MACI (Vericel Corporation):

LAVIV (Azficel-T) (Fibrocell Technologies):

Competitive Analysis

Covid-19 Impact Analysis

COVID-19 Impact Analysis

Challenges Analysis

Manufacturing & Supply Challenges

Opportunities analysis

Need For Development Of New Therapies Against SARS-COV-2

T-cell Therapy

Cell Therapy

Gene Therapy

Tissue engineering

Rise In Demand For Supply Chain Management Solutions

Challenges in Manufacturing T-cell Therapies Against COVID-19

Clinical Trial Analysis

Regenerative Medicine Market: Product Business Analysis

Regenerative Medicine Market: Therapeutic Category Business Analysis

Regenerative Medicine Market: Regional Business Analysis

Companies Mentioned

Integra Lifesciences Corporation

Astellas Pharma Inc.

Cook Biotech, Inc.

Bayer AG

Astrazeneca plc

F. Hoffmann-La Roche Ltd.

Pfizer, Inc.

Merck Kgaa

Abbott

Vericel Corporation

Novartis AG

GlaxoSmithKline plc.

Baxter International Inc.

Boehringer Ingelheim GmbH

Amgen Inc.

Cesca Therapeutics Inc. / Thermogenesis Holdings Inc.

U.S Stem Cell, Inc.

Bristol-Myers Squibb Company

Eli Lilly and Company

Nuvasive, Inc.

Organogenesis, Inc.

More here:
Worldwide Regenerative Medicine Outlook to 2027: Therapeutics Segment Dominated the Market in 2020 Due to the High Usage of Primary Cell-Based...

Posted in Regenerative Medicine | Comments Off on Worldwide Regenerative Medicine Outlook to 2027: Therapeutics Segment Dominated the Market in 2020 Due to the High Usage of Primary Cell-Based…

Artiva Biotherapeutics Strengthens Leadership Team with the Appointment of Christopher Horan as Chief Technical Operations Officer – Yahoo Finance

Posted: January 5, 2022 at 2:00 am

SAN DIEGO, January 04, 2022--(BUSINESS WIRE)--Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, today announced the appointment of Christopher Horan as Chief Technical Operations Officer. As a leader in therapeutic technical operations, Mr. Horan brings more than 30 years of experience managing complex systems and teams in support of biologics campaign manufacturing, supply chain management, and product distribution.

"I am very pleased to welcome Chris to our team," said Fred Aslan, M.D., CEO of Artiva. "His experience and leadership will be invaluable to us as we further establish our Manufacturing-First approach to off-the-shelf, NK cell therapeutics."

"We believe Chriss deep experience in managing the manufacture and supply of campaign manufactured biologic therapeutics and cell therapies will further advance Artivas goal of delivering highly-scaled NK and CAR-NK therapies to cancer patients with the logistical simplicity of traditional biologic products," said Peter Flynn, Ph.D., Cofounder and Chief Operating Officer of Artiva.

"Im excited to join Artiva, a leading company in the rapidly growing NK cell therapy field, and I look forward to working with the team as we work to further establish clinical and commercial supply from both Korean- and US-based manufacturing facilities," said Mr. Horan.

Mr. Horan spent nearly 14 years at Genentech, a member of the Roche Group, where he held several leadership positions across technical operations, including as Senior Vice President, Global Product and Supply Chain Management for Roche in Basel, Switzerland. In that role, he led a 480-person team supplying all of Roche biopharma products worldwide. He joins Artiva from SanBio, where, as Chief Technical Officer (CTO), he led the process development, manufacturing, supply, and quality systems for their mesenchymal stem cell regenerative medicine approach to brain injury in support of a near-term registration in Japan. Previous to SanBio, he was Chief Technical Operations Officer at Dermira, where he led all aspects of pharmaceutical sciences, manufacturing, quality, supply chain, and procurement to launch the companys first commercial product. He led the effort to prepare Dermiras IL-13 monoclonal antibody program for Phase 3 trials and commercial filing and had a key role in supporting the companys successful acquisition by Eli Lilly and Company. Mr. Horan started his career with over a decade of increasing responsibility in technical operations at Merck & Co.

Story continues

About Artiva Biotherapeutics

Artivas mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, utilizing our Manufacturing-First approach, that are safe and accessible to cancer patients. Artivas pipeline includes AB-101, an ADCC enhancer NK-cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers. Artiva is currently advancing a Phase 1/2 clinical trial of AB-101 in combination with rituximab for the treatment of relapsed or refractory B-cell lymphomas. Artivas pipeline also includes AB-201, an anti-HER2 CAR-NK cell therapy candidate for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers, and AB-202, a CD19-specific CAR-NK cell therapy candidate for the treatment of B-cell malignancies. The company has entered into therapeutic NK cell collaborations with Merck Sharp & Dohme Corp. and with Affimed GmbH. Artivas AlloNK platform incorporates cell expansion, activation, and engineering technology developed by Artivas strategic partner, GC Cell Corporation, a member of the GC family of companies, a leading healthcare company in Korea. Artiva is headquartered in San Diego. For more info, visit http://www.artivabio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005176/en/

Contacts

Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091Investors: Michael E. Faerm, Artiva Biotherapeutics, Inc., mfaerm@artivabio.com

Originally posted here:
Artiva Biotherapeutics Strengthens Leadership Team with the Appointment of Christopher Horan as Chief Technical Operations Officer - Yahoo Finance

Posted in Regenerative Medicine | Comments Off on Artiva Biotherapeutics Strengthens Leadership Team with the Appointment of Christopher Horan as Chief Technical Operations Officer – Yahoo Finance

Here’s 7 things the International Space Station taught us in 2021 – Space.com

Posted: January 5, 2022 at 2:00 am

The International Space Station is the world's most extreme and expensive scientific laboratory. In its more than 20 years of operations it has housed thousands of experiments, providing fascinating insights into the effects of microgravity on the human body, cultured cells or various materials and chemical processes. Here are the most interesting findings that the space station delivered in 2021.

Stem cells are sometimes seen as the holy grail of future medicine. Capable of almost endlessly regenerating and turning themselves into all sorts of cells, stem cells are abundant in young bodies but lose their vigor as we age. There are various types of stem cells. Those found in embryos, also called the pluripotent stem cells, can give rise to all kinds of cells in the human body. But stem cells exist in adult bodies too, ensuring the ability of various organs to repair themselves.

A recent experiment flown on the International Space Station found that in the weightless environment, stem cells from the human heart improved their ability to regenerate, survive and proliferate.

The effects were observed in both adult and neonatal stem cells. The discovery, part of NASA's Cardiac Stem Cells research project, is good news for the future of regenerative medicine as it shows that it is possible to kick adult heart stem cells into better action. That is to increase their 'stemness', their ability to regenerate, proliferate and create new types of cells that a damaged organ might need. Regenerative medicine hopes to one day be able to engineer tissue to repair and replace failing organs and cells. The study was published in the International Journal of Molecular Sciences.

Related: What does space do to the human body? 29 studies investigate the effects of exploration

Microgravity is bad news for bones. The lack of mechanical loading tells the body to stop maintaining these important support structures since they don't seem to be needed. When astronauts return to Earth, they suffer from serious bone loss.

The good news is, that just like on Earth, exercising in space seems to keep the body fit, including the bones. A new study published in the British Journal of Sports Medicine revealed that crew members who increased their resistance training during their space missions were more likely to preserve their bone strength.

The study, part of NASA's Biochem Profile and the Canadian Space Agency's TBone investigations, also found that bone loss in some astronauts could be predicted by the elevation of certain biomarkers before their flight. These biomarkers, found in the astronauts' blood and urine, together with the astronauts' exercise history could help space surgeons identify astronauts at greater risk for bone loss.

Microbes can efficiently extract valuable metals from lunar and martian rocks in space, a recent experiment by the European Space Agency (ESA) revealed. The experiment, called Biorock, used microorganisms to extract the metal element vanadium from basalt, which can be commonly found on the moon and Mars.

The microbes extracted 283% more vanadium while on the space station than on Earth. Biomining is a cheaper and more environmentally friendly alternative to chemical extraction of important materials from ores, a process that usually relies on harsh chemicals and requires a lot of energy. Using biomining in space will surely come handy to future Mars and moon colonists as they will be able to get raw materials for making tools, spacecraft parts and other equipment.

A European instrument called the Atmosphere-Space Interactions Monitor (ASIM) has provided new insights into the genesis of some little understood phenomena in Earth's atmosphere. Used to study severe thunderstorms and their atmospheric effects, ASIM previously helped shed light on the generation of high-energy terrestrial gamma-ray flashes (TGFs), the most energetic natural phenomena on Earth that accompany lightings during thunderstorms.

But more recently, the instrument studied the so-called blue jets, which are essentially upward shooting bursts of lighting generated by disturbances of positively and negatively charged regions in the tops of the clouds. Blue jets, which get their characteristic blue color from nitrogen ions, can shoot up to altitudes of 30 miles (50 kilometers) in less than a second.

Scientists found that the blue jets are generated by "blue bangs," short discharges in the upper layers of storm clouds. The mechanism behind these blue jets appears to be somewhat different from that behind normal lightning that we can observe on the ground.

Astronauts on the International Space Station experimented with making cement in space and found that although it creates somewhat different microstructures than on Earth, it works. The experiment, called Microgravity Investigation of Cement Solidification (MICS), involved mixing cement powders with various additives and different amounts of water.

In the latest round of experiments, a mixture of tricalcium aluminate and gypsum showed interesting results.

In the future, these "made in space" cement blends could be used to build stations on Mars or the moon. Cement is used to make concrete, which has excellent shielding properties against cosmic radiation. It is also strong enough to protect against impacting meteorites.

And to make things easy, future Mars and moon colonists could actually 3D-print structures from concrete made from lunar and martian soils in a 3D printer similar to the Additive Manufacturing Facility that is currently on the space station.

New space station research has shown that the technology used to shield astronauts from dangerous space radiation can be made even more efficient in the future using a mineral called colemanite. This boron-rich mineral is a type of borax that forms as a deposit during evaporation of alkaline water.

An experiment by the Japan Aerospace Exploration Agency (JAXA) exposed several pieces of a polymer material to space conditions outside the International Space Station. The polymer sample treated with colemanite suffered almost no radiation damage and looked nearly indistinguishable from a sample that was not exposed to space. The researchers published their results in the Journal of Applied Polymer Science in July.

In the future, colemanite could be used to treat satellites, space station exteriors or even high altitude planes, NASA said in a statement.

Astronauts and cosmonauts in space frequently suffer from changes to the structure of their veins, especially in their legs. A study by the Russian space agency Roscosmos, however, found that these changes can be somewhat prevented by exercise and can be reversed post-flight if the space travellers have enough time off between missions.

The veins of the 11 cosmonauts that participated in this study, published in the journal Experimental and Theoretical Research, didn't show worse damage after the second flight compared to the first. The spacefarers had breaks of about 4 years between their missions.

Follow Tereza Pultarova on Twitter @TerezaPultarova. Follow us on Twitter @Spacedotcom and on Facebook.

See the original post here:
Here's 7 things the International Space Station taught us in 2021 - Space.com

Posted in Regenerative Medicine | Comments Off on Here’s 7 things the International Space Station taught us in 2021 – Space.com

Organoids Market is Projected to Expand at a High CAGR from 2020 to 2030 – Digital Journal

Posted: January 5, 2022 at 2:00 am

Organoids Market: Introduction

According to the report, the globalorganoids marketwas valued over US$ 1.7 Bn in 2019 and is projected to expand at a high CAGR from 2020 to 2030. Organoids are replicated or miniaturized versions of organs such as stomach, liver, lung, kidney, and brain produced from stems cells in vitro. These miniature models are three-dimensional tissue culture derived from stem cells. The stem cells are derived from pluripotent and organ specific stem cells. The global organoids market is driven by rise in prevalence of various diseases, sudden outbreak of infectious diseases in 2020, and development of organoid models for studying various disease modeling, which are expected to boost the organoids market during the forecast period. Technological advancements leading to the development of organoids for diagnosis and studying patient-derived tumors.

Request Brochure of Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=73363

North America dominated the global organoids market in 2019, followed by Europe and Asia Pacific. North Americas dominance can be ascribed to technological advancements, development & adoption of organoid models that resemble various organs, and high clinical R&D expenditure by both governments and private players are likely to drive the organoids market in North America during the forecast period.

Organoids as Therapeutic Tools to Drive Global Market

Organoids are considered prominent tools for discovery of drugs, diagnosis, and development of treatment for various chronic diseases. Rise in prevalence and increase in incidence of various diseases drive scientists and researchers to continue research on organoid models to study human physiology and disease modeling. Organoids are considered innovative approach for drug discovery, disease modeling through stem cell research, and innovating personalized medicines. These factors enable faster adoption of organoids as therapeutic tools across the globe. Amidst the COVID-19 pandemic, researchers are using organoids as prominent tools to study the coronavirus disease, modelling, and development of treatment. Organoids are considered powerful tools for respiratory diseases or infections. These factors are anticipated to propel the global organoids market.

Request for Analysis of COVID-19 Impact on Organoids Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=73363

Organoids Market: Prominent Regions

The global organoids market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global organoids market in 2019, followed by Europe and Asia Pacific. The presence of prominent players conducting various studies using organoid models is a major factor boosting the growth of the organoids market in North America. In April 2020, STEMCELL Technologies, Inc. conducted projects in alliance with the University of British Columbia (UBC) atGenome British Columbia for testing thousands of FDA-approved drugs and clinical stage compounds alone or in combination for drug repurposing against SARS-CoV-2 infection by using human organoid culture technology.

The organoids market in Europe is anticipated to expand at a high CAGR from 2020 to 2030. The presence of key players offering organoids, technological advancements, large patient pool, increase in the geriatric population, and rise in prevalence of chronic diseases are anticipated to boost the growth of the organoids market in the region. Moreover, the company offers innovative portfolio of organoid models for drug screening, development of regenerative medicine, personalized medicine, and other therapeutic application. This is expected to fuel the growth of the organoids market in Europe during the forecast period.

Buy Organoids Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=73363&ltype=S

Investments toward Development of Innovative Organoid Product Offerings and Geographic Presence of Key Players to Drive Global Market

The global organoids market is consolidated in terms of number of players. The market is dominated by key players with innovative product offerings, robust geographic presence, and large investments in research & development. Leading players operating in the global organoids market include STEMCELL Technologies Inc., Cellesce Ltd., Hubrecht Organoid Technology, Definigen, 3Dnamics, Inc., Organoid Therapeutics, PeproTech, Inc., Thermo Fisher Scientific, Corning Incorporated (Life Sciences), and Merck KGgA. Prominent players have introduced innovative organoid models amidst the COVID-19 pandemic to study the disease pathology and develop innovative treatment. Moreover, companies are investing in continuous research & development for wide therapeutic applications.

In February 2020, Cellesce Ltd. published application of patient-derived organoids in the early cancer drug discovery, which would offer significant benefits to cancer patients. The company invests in continuous research and development for identifying tumor derived organoid as a novel solution for the drug discovery and its benefits in the cancer research.

More Trending Reports by Transparency Market Research

Diabetes Drugs Market:

https://www.transparencymarketresearch.com/diabetes-drug-market.html

Gestational Diabetes Treatment Market:

https://www.transparencymarketresearch.com/gestational-diabetes-treatment-market.html

Cardiopulmonary Stress Testing Systems Market:

https://www.transparencymarketresearch.com/cardiopulmonary-stress-testing-systems-market.html

About Us:

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information.Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Upfor a 7 day free trial!

Contact Us

Mr. Rohit BhiseyTransparency Market Research,90 State Street, Suite 700,Albany, NY 12207Tel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite:https://www.transparencymarketresearch.com/

See the rest here:
Organoids Market is Projected to Expand at a High CAGR from 2020 to 2030 - Digital Journal

Posted in Regenerative Medicine | Comments Off on Organoids Market is Projected to Expand at a High CAGR from 2020 to 2030 – Digital Journal

4BIO Capital Leads $6 Million Seed Financing in Ray Therapeutics – GlobeNewswire

Posted: January 5, 2022 at 2:00 am

Press Release

4BIO Capital Leads $6 Million Seed Financing in Ray Therapeutics

4 January 2022

LONDON & BOSTON 4BIO Capital (4BIO or the Group), an international venture capital firm focused solely on the advanced therapies sector, today announces that it has led a $6 million seed financing round in Ray Therapeutics (or the Company), a biotech company developing optogenetic gene therapies for patients with blinding diseases.

The funding will be used to advance its optogenetic therapy, Ray-001, into clinical trials in retinitis pigmentosa (RP). Based on the durability of treatment demonstrated in preclinical studies, Ray-001 is intended to be a one-time treatment via intravitreal injection that is sustainable for a lifetime. Unlike current RP gene therapies in development, which are targeted to specific genetic mutations or individuals with remaining photoreceptors that only address a small patient population, Ray-001 is mutation-agnostic.

Optogenetics is a promising approach that has the potential to restore useful vision to visually-impaired and blind individuals. In RP, a patients photoreceptors, the primary cells required for vision, are lost and cannot regenerate. However, inner retinal neurons downstream to photoreceptors, especially retinal ganglion cells (RGCs), persist in significant numbers even in late-stage disease. Ray Therapeutics lead candidate Ray-001 uses an intravitreal approach where it diffuses from the vitreous into the retina and transduces primarily the RGCs.

Dr Dmitry Kuzmin, Managing Partner at 4BIO Capital, commented: Were excited to invest in Ray Therapeutics, which is developing a ground-breaking new approach to treat inherited retinal diseases using the power of optogenetics. Rays experienced management team have a successful track record in developing regenerative medicines in ophthalmology indications including optogenetic therapies. As a mutation-agnostic approach, Ray-001 has a significant advantage in that it can potentially treat more patients as a one-time intravitreal injection that will last for a lifetime.

Paul Bresge, CEO & Co-Founder at Ray Therapeutics, said: This seed financing round led by top-tier advanced therapies investor 4BIO Capital, enables us to advance our optogenetic gene therapy platform, pipeline and people. Im thrilled to be leading a team to develop our optogenetic gene therapy, Ray-001, which could potentially restore vision for patients with blinding diseases, beginning with retinitis pigmentosa, an area of significant unmet medical need.

-Ends-

Contacts

About Retinitis Pigmentosa

Retinitis pigmentosa (RP), is a heterogeneous group of genetic diseases that cause retinal degeneration leading to near or complete blindness for most patients. The severe loss of photoreceptor cells that occurs in this genetic degenerative disease leads to partial or complete blindness. At present, no effective treatment is available to restore vision once the photoreceptor cells have been lost. Over 100 genetic mutations are known to cause RP and all types of inheritance patterns are recognized. Patients are typically diagnosed in their late teens, with symptoms including night blindness, reduced visual fields and eventual loss of visual acuity. As the disease progresses, retinal atrophy, and permanent loss of the light sensitive photoreceptors occur. The prevalence of RP is approximately 100,000 persons affected in the US.

About 4BIO Capital

4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector.

4BIOs objective is to invest in, support, and grow early stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome.

The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine. 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space.

For more information, please visit http://www.4biocapital.com

About Ray Therapeutics

Ray Therapeutics is developing novel optogenetics gene therapies for patients with blinding diseases. The company is developing its lead candidate Ray-001 in retinitis pigmentosa, a degenerative retinal disease with significant unmet medical need. The companys mission is to use optogenetics to restore vision, agnostic of genetic mutation for patients with inherited retinal diseases. Ray Therapeutics is based in San Diego, CA. For additional information, please visit http://www.raytherapeutics.com.

Originally posted here:
4BIO Capital Leads $6 Million Seed Financing in Ray Therapeutics - GlobeNewswire

Posted in Regenerative Medicine | Comments Off on 4BIO Capital Leads $6 Million Seed Financing in Ray Therapeutics – GlobeNewswire

Biotech Executive to Join Yulex – PRNewswire

Posted: January 5, 2022 at 2:00 am

SAN DIEGO, Jan. 3, 2022 /PRNewswire/ --YULEX, LLC a leading materials science company using certified supply chains for the production of sustainable plant-based materials to replace petroleum based products, today announced that Liz Bui, Esq. Ph.D. will be joining the company as Chief Business Officer, effective immediately.

Dr. Liz Bui joins from ViaCyte, Inc., a regenerative medicine company, where she was Vice President, IP Counsel and later also Diversity & Inclusion Officer for 15 years. Prior to Viacyte, Dr. Bui was an associate at the global law firm of DLA Piper. She brings 20 years of business experience in the area of biotechnology and associated intellectual property development and corporate transactions including technology licensing.

"Liz joins the Yulex team at a critical inflection point in our growth. The pandemic has focused consumer brands on the intersection of climate change and human health and they are seeking material technologies that can reduce the impact of carbon emissions, minimize toxic emissions and eliminate, wherever possible, the use of plastics," said Jeff Martin, Founder & CEO of Yulex, LLC. "In addition to her business background, Liz' experiences in equity, diversity, inclusion will assist Yulex in promoting best environmental and social practices in our global supply chain."

"I am excited to extend my experience from biotech to consumer facing industries impacting both human and environmental health. Yulex is delivering innovative plant-based materials and engineered solutions for multiple market segments," said Dr. Bui.

Dr. Bui received her Ph.D. from UCLA and her J.D. from Pepperdine Law School. She is also an Adjunct Professor at the University of San Diego School of Law and the University of Dayton School of Law. Liz has served on the boards of the Boz Institute- Life Science Research and Teaching Institute, the Vietnamese Bar Association of Southern California, the Newcomb Alumnae Association Board (Tulane University), Toussaint Academy of San Diego, and the School for Entrepreneurship and Technology.

About Yulex LLC:Engineering high-performance plant-based products for a better planet. At Yulex, we have a must-do ethos about solving challenging environmental problems including the negative effects that petroleum-based materials have on the planet and its people. We focus on the responsible development of processes to create better and safer products.

Jeff MartinYulex LLC760.889.9651[emailprotected]

SOURCE Yulex, LLC

Originally posted here:
Biotech Executive to Join Yulex - PRNewswire

Posted in Regenerative Medicine | Comments Off on Biotech Executive to Join Yulex – PRNewswire

EDUCATION SPOTLIGHT: Florida Tech Highlights Work Done During 2021 as We Enter the New Year – SpaceCoastDaily.com

Posted: January 5, 2022 at 1:59 am

education spotlightAs we enter 2022, below are some Florida Tech research highlights from 2021. (Florida Tech image)

BREVARD COUNTY MELBOURNE, FLORIDA As we enter 2022, here are some Florida Tech research highlights from 2021.

At the Orbital Robotic Interaction, On-orbit servicing, and Navigation (ORION) lab, multiple of space-related research projects are underway, led by Markus Wilde, aerospace, physics, and space sciences associate professor.

One of the current projects is a parabolic flight experiment funded by NASA, called the Autonomous Multi-Cycle Farming System.

The team, consisting of Wilde, mechanical and civil engineering assistant professor Hamidreza Najafi, and aerospace, mechanical engineering, and computer science student researchers, took a 2020 Senior Design project, a modified 3D printer to implant and nurture plant seeds into water-filled feed trays in space, and are turning it into an experiment for a parabolic flight.

Brian Kish, an aerospace, physics, and space sciences associate professor is supporting the project with flight testing.

According to Wilde, the feed trays have been successful in growing plants and the team plans to fly in late November or early December this year.

What we are going to show with that parabolic flight is that the planting mechanism works fine in microgravity and that the system is able to function through changes from zero gravity to 2Gs, Wilde said.

The cool thing is that these parabolic flights also provide Martian gravity and moon gravity, so were going to be able to show the system works on orbit, on the moon, and on Mars.

As the focus on climate change and electric transportation increases, the first-in-the-nation acquisition for Florida Tech will allow for hands-on learning and important research on a new and timely aspect of aviation.

In August, the school became the only American university to own and fly an electric plane. The Velis Electro, a light aircraft from the Slovenian company Pipistrel, was introduced last year.

The first electric-powered airplane certified in Europe, it has a maximum speed of 181 km/h (113 mph, 98 knots), zero emissions, an engine with a noise level of 60 decibels (quieter than the single-engine Cessna 172 which is 85 decibels) and a body made of composite materials. The plane costs $190,000.

The two-seater has not been flown in the United States until now. It is awaiting U.S. certification, so Florida Tech is flying it under the experimental category.

Florida Tech alumnus and former associate dean Isaac Silver was the pilot for the inaugural flight. He flew for 22 minutes, using about a third of the aircrafts battery capacity and creating an operating cost of only $1.03.

The plan will give students the opportunity for experiential research with cutting-edge technology, providing a research value added to their educational experience.

While we can teach students flight test techniques using older aircraft, having them test an airplane with the latest technology prepares them for contemporary designs, said Brian Kish, Flight Test Engineering program chair and aerospace associate professor. For more, click here.

As reefs face threats from climate change, Florida Tech is exploring 3D printing to potentially help sustain this critical but threatened ocean resource.

Ocean engineering and marine sciences professor Stephen Wood and research students John Carroll, Sydney Goodman, Gabija Karosas, Alexa Langley, August Neier, and Katherine Tyson are proposing to use a 3D printer to make coral structures that would then be placed upon large mounds of concrete in the ocean.

The goal is to design a production method in which creating artificial coral reefs is accessible and affordable, and using 3D printing would decrease the time to produce artificial corals.

The team is working to build a printer that is much larger than common printers on the market, which will allow them to print life-size corals.

To reach their goals, the team assembled a smaller 3D printer to familiarize themselves with the mechanisms and construction of 3D printing.

They then designed a full-scale 3D printer to print in ceramic, though there is a future option to print in concrete.

Mixing engineering and coral biology, the researchers looked at different 3D-printer parts and filament materials as they would relate to various corals and designs, and they also considered how the printed products would react in the ocean environment.

The team also used a sample printer to print small models of corals, which represent the final print concept.

While the printed corals may not look identical to the real thing, they will be designed with an important goal in mind: facilitate coral growth.

We may print out the base structure of the coral, like an Elkhorn coral, we could print a good majority of that, so when the little polyps adhere, they could grow off of that, Wood said. For more, click here.

Facial recognition and analysis, and the machine learning techniques behind them, have many applications, from affirming identity documents to unlocking mobile phones.

Now, this technology may have the power to help doctors better understand and diagnose neurodegenerative diseases.

Diego Guarn, assistant professor in the biomedical engineering program, has been working on using facial recognition and analysis and machine learning algorithms to evaluate the effects of different neurodegenerative and motor disorders in speech production and facial movements.

The overall goal of Guarns research is to use facial recognition techniques to analyze if patients have neurodegenerative or motor disorders, such as Bells palsy, Parkinsons disease, and ALS.

Using this new technology would allow doctors to provide more effective care to individuals who are developing these diseases, as well as to track disease progression and provide a baseline to see if those with the disease are improving with treatment.

Using an artificial neural network to find a specific location on the face, Guarn then uses the recognition technology to track how the person moves their face.

His experiments are currently performed in well-controlled environments, such as a room with a good camera, low noise, and proper illumination. Guarns next work will involve testing these approaches to detect neurodegenerative diseases in home environments during a video call.

The patients are going to perform certain exercises in front of the camera, such as opening their mouth and saying some sentences, he said.

The computer is going to track how the patient moves their mouth and face, and then were going to have an idea of if that movement belongs to a healthy individual in their age group or if that movement belongs to a person with a specific disease. For more, click here.

There is an urgent need to develop sustainable agricultural practices and ensure food security at a much higher level than has ever been attempted or required.

According to a study conducted by Bisk College of Business assistant professor Darrell Burrell and others, this leap might only be possible with the rapid development and application of cutting-edge technologies, including artificial intelligence (AI).

Burrell, along with colleagues from Grand Canyon University, Temple University, and Illinois Institute of Technology, published Exploring technological management innovations that include artificial intelligence and other innovations in global food production, in the International Journal of Society Systems Science last year.

The research offered new data on technological innovations that may help overcome agricultural concerns for meeting a process improvement initiative.

The study analyzed technologies being used to increase food production and included insights from those in the industry.

The research found there were several AI-related systems that are used in farming, ranging from drones surveying the crops to solar panels and sunset-triggered irrigation to motion sensor technology that serves as a digital scarecrow by scaring birds away from crops with a simulated human yell.

The paper even looked at robots picking crops.

The things that Ive seen in my research are the ability to capitalize on technologies that were maybe intended for one purpose but are now being used for another, Burrell said.

The ability to use drones to survey your farm actually makes things more efficient. Instead of me having maybe five people inspecting my farm, I could sit in my farmhouse and use this drone to inspect and review what is going on. For more, click here.

Our brain is made of millions of cells called neurons. Neurons send electrical messages to talk to each other in patterns of vertical electric activity called oscillations.

By inducing them first, then finding the amplitude of the specific brain waves improved during memory, ultimately memory performance itself is boosted. Once introduced, what if a person can boost the speed of these oscillations to improve memory? A university study in a journal for adolescents may show we can do just that.

Psychology assistant professor Rick Addante and clinical psychology doctoral student Mairy Yousif, along with researchers from California State University, San Bernardino, looked at the brain-boosting potential in the research paper, Boosting Brain Waves Improves Memory.

The paper was published in the November 2021 edition of Frontiers for Young Minds, an open-access scientific journal written by scientists and reviewed by a board of kids, teens, and expert scientists.

As the largest impact journal in the entire Frontiers system, this allows for more (and younger) eyes to look at new scientific research that is not often seen by the masses.

The original empirical discovery was published as a technical report, but this version was specially developed and written for accessibility to public STEM audiences.

[Cognitive neuroscience is] a pretty niche field and we dont get a lot of exposure and readership on what the discoveries are, but through this journal that theyve developed, they can get millions of downloads per month of individual articles because its free, its open access to kids all around the world, Addante said.

The team analyzed if memory could improve by stimulating the brain using flashes of lights and sounds that caused the brainwaves to be in sync.

People received rhythmic brain stimulation in special goggles and heard auditory beeps in headphones. This process, known as entrainment, trains the brain to be in sync at a specific wave pattern called theta.

People whose brains were trained to be in theta showed improved memory compared to people receiving random stimulation.

The team found that entrainment can safely manipulate brain waves to improve peoples memory, which opens the possibility of using devices like the ones researched for helping people who suffer from memory disorders. For more, click here.

CLICK HERE FOR BREVARD COUNTY NEWS

Read more from the original source:
EDUCATION SPOTLIGHT: Florida Tech Highlights Work Done During 2021 as We Enter the New Year - SpaceCoastDaily.com

Posted in Florida Stem Cells | Comments Off on EDUCATION SPOTLIGHT: Florida Tech Highlights Work Done During 2021 as We Enter the New Year – SpaceCoastDaily.com

Mayo Clinic uses stem cell therapy to treat arthritis in …

Posted: January 5, 2022 at 1:57 am

Researchers at Mayo Clinic's campus in Florida have conducted the world's first prospective, blinded and placebo-controlled clinical study to test the benefit of using bone marrow stem cells to reduce arthritic pain and disability in knees.

It is the first time that the belief that stem cells can provide substantial and possible regenerative relief in an ailing joint has been put to the test in such a rigorous fashion. The researchers say such testing is needed because there are at least 600 stem cell clinics in the U.S. offering one form of stem cell therapy or another to an estimated 100,000-plus patients, who pay thousands of dollars, out of pocket, for the treatment, which has not undergone demanding clinical study.

The findings in The American Journal of Sports Medicine represent another first patients not only had a dramatic improvement in the knee that received stem cells, but also in their other knee, which also had painful arthritis but received only a saline control injection. Each of the 25 patients enrolled in the study had two bad knees, but did not know which knee received the stem cells.

Given that the stem cell-treated knee was no better than the control-treated knee both were dramatically better than before the study began the researchers say the stem cells' effectiveness remains somewhat uninterpretable. They are only able to conclude the procedure is safe to undergo as an option for knee pain, but they cannot yet recommend it for routine arthritis care.

Our findings can be interrupted in ways that we now need to test one of which is that bone marrow stem cell injection in one ailing knee can relieve pain in both affected knees in a systemic or whole-body fashion, says the study's lead author, Shane A. Shapiro, M.D., a Mayo Clinic orthopedic physician.

The rest is here:
Mayo Clinic uses stem cell therapy to treat arthritis in ...

Posted in Stem Cell Therapy | Comments Off on Mayo Clinic uses stem cell therapy to treat arthritis in …

Page 553«..1020..552553554555..560570..»